MX381872B - Mutantes de neumolisina y metodos de uso de los mismos. - Google Patents
Mutantes de neumolisina y metodos de uso de los mismos.Info
- Publication number
- MX381872B MX381872B MX2017006625A MX2017006625A MX381872B MX 381872 B MX381872 B MX 381872B MX 2017006625 A MX2017006625 A MX 2017006625A MX 2017006625 A MX2017006625 A MX 2017006625A MX 381872 B MX381872 B MX 381872B
- Authority
- MX
- Mexico
- Prior art keywords
- mutants
- methods
- pneumolysin
- various embodiments
- present
- Prior art date
Links
- 101710183389 Pneumolysin Proteins 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082848P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/061859 WO2016081839A1 (en) | 2014-11-21 | 2015-11-20 | Pneumolysin mutants and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017006625A MX2017006625A (es) | 2018-01-15 |
| MX381872B true MX381872B (es) | 2025-03-13 |
Family
ID=56014598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006625A MX381872B (es) | 2014-11-21 | 2015-11-20 | Mutantes de neumolisina y metodos de uso de los mismos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10562941B2 (enExample) |
| EP (2) | EP3220937B1 (enExample) |
| JP (1) | JP6734274B2 (enExample) |
| KR (1) | KR102304828B1 (enExample) |
| CN (1) | CN107106635B (enExample) |
| AU (1) | AU2015349787B2 (enExample) |
| CA (1) | CA2968398A1 (enExample) |
| DK (1) | DK3220937T3 (enExample) |
| ES (1) | ES2993430T3 (enExample) |
| FI (1) | FI3220937T3 (enExample) |
| HR (1) | HRP20241627T1 (enExample) |
| HU (1) | HUE069200T2 (enExample) |
| LT (1) | LT3220937T (enExample) |
| MX (1) | MX381872B (enExample) |
| PL (1) | PL3220937T3 (enExample) |
| PT (1) | PT3220937T (enExample) |
| RS (1) | RS66221B1 (enExample) |
| SI (1) | SI3220937T1 (enExample) |
| SM (1) | SMT202400482T1 (enExample) |
| WO (1) | WO2016081839A1 (enExample) |
| ZA (1) | ZA201703881B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| EP3562838A2 (en) | 2016-12-28 | 2019-11-06 | Henriques Normark, Birgitta | Microparticles from streptococcus pneumoniae as vaccine antigens |
| CN110967482B (zh) * | 2018-09-30 | 2023-04-07 | 重庆市畜牧科学院 | 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法 |
| CN113264999B (zh) * | 2021-04-29 | 2023-02-28 | 星济生物(苏州)有限公司 | 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途 |
| WO2023039223A1 (en) * | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
| KR20240149460A (ko) | 2021-11-18 | 2024-10-14 | 매트리박스, 인크. | 면역원성 융합 단백질 조성물 및 이의 사용 방법 |
| CN115927420A (zh) * | 2022-05-27 | 2023-04-07 | 贵州省畜牧兽医研究所 | 一种溶血素重组表达及间接elisa检测方法及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686102A (en) | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| US6716432B1 (en) | 1988-12-16 | 2004-04-06 | James Cleland Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| EP0449856B1 (en) | 1988-12-16 | 2001-09-12 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| US5854416A (en) | 1991-11-14 | 1998-12-29 | The United States Of America As Represented By The Department Of Health And Human Services | Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor |
| US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
| ES2239332T3 (es) | 1995-06-07 | 2005-09-16 | Regents Of The University Of Minnesota | Mutantes de la toxina de estreptococos a y procedimientos de uso. |
| KR100619350B1 (ko) | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
| US6224880B1 (en) | 1997-09-24 | 2001-05-01 | Merck & Co., Inc. | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines |
| US6903184B1 (en) | 1998-03-02 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| CA2341268C (en) | 1998-07-22 | 2010-10-12 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Streptococcus suis vaccines and diagnostic tests |
| ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
| US6887480B1 (en) | 1999-06-10 | 2005-05-03 | Medimmune, Inc. | Streptococcus pneumoniae proteins and vaccines |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| EP1558280B1 (en) | 2002-11-07 | 2014-01-08 | Synergy America, Inc. | Compositions and methods for treating or preventing pneumococcal infection |
| US20060257421A1 (en) | 2004-02-13 | 2006-11-16 | Martina Ochs | Pneumolysin derivatives |
| GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| WO2005108419A1 (en) | 2004-05-07 | 2005-11-17 | Lea-Ann Kirkham | Mutant cholesterol-binding cytolysin proteins |
| US9370557B2 (en) | 2006-06-15 | 2016-06-21 | The University Court Of The University Of Glasgow | Adjuvant compounds |
| AU2008287286B2 (en) * | 2007-04-13 | 2013-10-10 | The Board Of Regents Of The University Of Oklahoma | Mutants of cholesterol-dependent cytolysins and uses thereof |
| WO2010071986A1 (en) * | 2008-12-24 | 2010-07-01 | Sanofi Pasteur Limited | Modified steptococcus pneumonia pneumolysin (ply) polypeptides |
| CN102939105B (zh) * | 2009-12-22 | 2016-11-16 | 赛诺菲巴斯德有限公司 | 免疫原性组合物和相关的方法 |
| CL2010001216A1 (es) * | 2010-11-08 | 2011-01-28 | New Tech Copper S P A | Sistema para confinar el espacio sobre el electrolito en una celda de electro obtencion y evacuar los aerosoles generados, que comprende un confinador insertado en cada anodo, con un par de proyecciones flexibles y un par de perfiles en angulo, y ductos longitudinales con perforaciones sobre el nivel del electrolito. |
| WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| JP6397805B2 (ja) | 2015-08-28 | 2018-09-26 | 東芝メモリ株式会社 | 半導体製造装置およびその運転方法 |
-
2015
- 2015-11-20 AU AU2015349787A patent/AU2015349787B2/en active Active
- 2015-11-20 JP JP2017527259A patent/JP6734274B2/ja active Active
- 2015-11-20 DK DK15861711.8T patent/DK3220937T3/da active
- 2015-11-20 CN CN201580071394.2A patent/CN107106635B/zh active Active
- 2015-11-20 WO PCT/US2015/061859 patent/WO2016081839A1/en not_active Ceased
- 2015-11-20 RS RS20241316A patent/RS66221B1/sr unknown
- 2015-11-20 EP EP15861711.8A patent/EP3220937B1/en active Active
- 2015-11-20 CA CA2968398A patent/CA2968398A1/en active Pending
- 2015-11-20 SI SI201532045T patent/SI3220937T1/sl unknown
- 2015-11-20 HU HUE15861711A patent/HUE069200T2/hu unknown
- 2015-11-20 EP EP24198287.5A patent/EP4501949A3/en active Pending
- 2015-11-20 MX MX2017006625A patent/MX381872B/es unknown
- 2015-11-20 PL PL15861711.8T patent/PL3220937T3/pl unknown
- 2015-11-20 PT PT158617118T patent/PT3220937T/pt unknown
- 2015-11-20 HR HRP20241627TT patent/HRP20241627T1/hr unknown
- 2015-11-20 KR KR1020177016881A patent/KR102304828B1/ko active Active
- 2015-11-20 FI FIEP15861711.8T patent/FI3220937T3/fi active
- 2015-11-20 SM SM20240482T patent/SMT202400482T1/it unknown
- 2015-11-20 US US15/527,919 patent/US10562941B2/en active Active
- 2015-11-20 ES ES15861711T patent/ES2993430T3/es active Active
- 2015-11-20 LT LTEPPCT/US2015/061859T patent/LT3220937T/lt unknown
-
2017
- 2017-06-06 ZA ZA2017/03881A patent/ZA201703881B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10562941B2 (en) | 2020-02-18 |
| PT3220937T (pt) | 2024-11-18 |
| US20180312552A1 (en) | 2018-11-01 |
| EP4501949A2 (en) | 2025-02-05 |
| SMT202400482T1 (it) | 2025-01-14 |
| JP6734274B2 (ja) | 2020-08-05 |
| CN107106635B (zh) | 2021-10-08 |
| KR102304828B1 (ko) | 2021-09-27 |
| ES2993430T3 (en) | 2024-12-30 |
| KR20170083635A (ko) | 2017-07-18 |
| FI3220937T3 (fi) | 2024-11-29 |
| AU2015349787B2 (en) | 2021-07-29 |
| WO2016081839A1 (en) | 2016-05-26 |
| MX2017006625A (es) | 2018-01-15 |
| HUE069200T2 (hu) | 2025-02-28 |
| BR112017010696A2 (pt) | 2017-12-26 |
| DK3220937T3 (da) | 2024-12-02 |
| LT3220937T (lt) | 2024-12-27 |
| JP2017536124A (ja) | 2017-12-07 |
| EP4501949A3 (en) | 2025-04-30 |
| AU2015349787A1 (en) | 2017-06-22 |
| RS66221B1 (sr) | 2024-12-31 |
| EP3220937A4 (en) | 2018-05-30 |
| HRP20241627T1 (hr) | 2025-02-14 |
| CA2968398A1 (en) | 2016-05-26 |
| SI3220937T1 (sl) | 2025-03-31 |
| EP3220937A1 (en) | 2017-09-27 |
| PL3220937T3 (pl) | 2025-01-27 |
| ZA201703881B (en) | 2021-10-27 |
| EP3220937B1 (en) | 2024-09-04 |
| CN107106635A (zh) | 2017-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381872B (es) | Mutantes de neumolisina y metodos de uso de los mismos. | |
| GB2547738B (en) | Improvements relating to camping assemblies | |
| IL261621A (en) | Genome edited immune effector cells | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| CL2016002252A1 (es) | Anticuerpos anti-egfrviii y usos de los mismos | |
| IL258666A (en) | Natural killer cells and ilc3 cells and uses thereof | |
| IL258434A (en) | Haploid induction compositions and methods for use therefor | |
| DK3194567T3 (da) | Probiotiske Bifidobacterium adolescentis-stammer | |
| BR112016021626A2 (pt) | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas | |
| PT3019619T (pt) | Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização | |
| IL247458A0 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
| EA201692254A1 (ru) | Иммуномодулирующие прогениторные (имп) клетки | |
| BR112016006614A2 (pt) | composições de trichoderma e métodos de uso | |
| IL259202A (en) | Modified immune cells and uses thereof | |
| PT3265123T (pt) | Anticorpos, usos e métodos | |
| ZA201805159B (en) | Mesenchymal stem cells as vaccine adjuvants and methods for using the same | |
| EP3438256A4 (en) | 3-EPIMERASE AND POLYNUCLEOTIDE CODING THEREOF | |
| EP3225551C0 (fr) | Ensemble de sièges á fauteuils agencés en quinconce | |
| BR112016019868A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso | |
| BR112017020896A2 (pt) | variantes de protoxina-ii e métodos de uso | |
| DK3498000T3 (da) | MRS-konfiguration i to niveauer | |
| DK3337487T3 (da) | Honokiol- og magnololformuleringer med øget stabilitet og forbedret optagelse og fremgangsmåder til anvendelse deraf | |
| PL3481219T3 (pl) | Piana zawierająca izolat protein rzepakowych |